Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LEVOTHYROXINE Cause Malignant neoplasm progression? 53 Reports in FDA Database

Thyroid Balance & Feminine Wellness

Thyrafemme Balance — 14 gentle ingredients for energy, mood & hormonal harmony.

Discover Thyrafemme

According to the FDA Adverse Event Reporting System (FAERS), 53 reports of Malignant neoplasm progression have been filed in association with LEVOTHYROXINE (LEVOTHYROXINE SODIUM). This represents 0.1% of all adverse event reports for LEVOTHYROXINE.

53
Reports of Malignant neoplasm progression with LEVOTHYROXINE
0.1%
of all LEVOTHYROXINE reports
10
Deaths
16
Hospitalizations

How Dangerous Is Malignant neoplasm progression From LEVOTHYROXINE?

Of the 53 reports, 10 (18.9%) resulted in death, 16 (30.2%) required hospitalization, and 4 (7.5%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LEVOTHYROXINE. However, 53 reports have been filed with the FAERS database.

What Other Side Effects Does LEVOTHYROXINE Cause?

Fatigue (10,494) Headache (6,425) Insomnia (4,663) Drug ineffective (4,556) Alopecia (4,491) Weight increased (4,130) Nausea (4,013) Palpitations (3,825) Dizziness (3,761) Asthenia (3,694)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which LEVOTHYROXINE Alternatives Have Lower Malignant neoplasm progression Risk?

LEVOTHYROXINE vs LEVOTHYROXINE\LEVOTHYROXINE LEVOTHYROXINE vs LEVOTHYROXINE\LIOTHYRONINE LEVOTHYROXINE vs LEVOXYL LEVOTHYROXINE vs LEXAPRO LEVOTHYROXINE vs LEXISCAN

Related Pages

LEVOTHYROXINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression LEVOTHYROXINE Demographics